SCHEMBL10183329

SCHEMBL10183329

CN(C)C(=O)Oc1ccc(CC(=O)N(c2cccc(F)c2)C2C(=O)N(C3CCCCC3)c3ccccc32)cc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CCKBR P32239 1/20 0.36
▸ OPRM1 P35372 2/20 0.35
▸ OPRK1 P41145 2/20 0.35
▸ OPRL1 P41146 2/20 0.35
▸ AGTR2 P50052 2/20 0.35
▸ HTR2A P28223 4/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ BCHE P06276 2/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ CYP2D6 P10635 1/20 0.32
▸ CCR3 P51677 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10184034 0.93 CCKBR (0.36) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10183321 0.88 OPRM1 (0.37) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10184038 0.87 KMT2A (0.36) CCKBRITGB1ITGA4IDH1CYP2D6
SCHEMBL10183783 0.82 OPRM1 (0.39) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10183299 0.82 OPRM1 (0.40) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10185587 0.82 TRPM8 (0.41) CCKBROPRM1OPRK1OPRL1
SCHEMBL10183320 0.82 AGTR2 (0.40) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10185957 0.82 TSHR (0.43) OPRM1OPRK1OPRL1IDH1
SCHEMBL10183319 0.81 MEN1 (0.43) CCKBROPRM1OPRK1OPRL1AGTR2
SCHEMBL10183337 0.81 OPRM1 (0.39) CCKBROPRM1OPRK1OPRL1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012009678-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS, INC. (US) 2012-01-19 — — WO disclosed
Send feedback